This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, Aug. 24, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (OTCBB:TGTX) today announced a poster presentation at the 7
th International Workshop on Waldenström's Macroglobulinemia (WM), held in Newport, RI. The poster entitled "
Role of NK-mediated ADCC in Waldenström's Macroglobulinemia Patients: Evidence Supporting a Therapeutic Strategy" was presented by Professor Veronique Leblond, MD, PhD, Head of Hematology, Hospital Pitié-Salpêtrière, Paris, France. Ublituximab, a novel, third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen, has been bioengineered for enhanced biological activity with an increased ability to trigger an immune response, delivering superior ADCC effects to aid in B-cell depletion.
Anti-CD20 monoclonal antibodies have several potential mechanisms of action, including ADCC which involves recruitment of effector cells such as Natural Killer (NK) cells to deplete circulating B-lymphocytes. This study evaluated the ADCC recruitment of NK cells in the presence of ublituximab in comparison to rituximab. Data presented at the meeting demonstrated that ublituximab is more efficient than rituximab in inducing ADCC at low doses and more importantly, results suggest that ublituximab could be more efficient than rituximab both to induce NK cell degranulation and ADCC in the presence of autologous peripheral tumor cells.
"Anti-CD20 monoclonal antibody therapy is a critical treatment component in WM; however patients continue to relapse. This data highlights the excitement for ublituximab, a new optimized anti-CD20 monoclonal antibody in the treatment of WM," stated Professor Leblond.
Ublituximab is a novel, third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen found on B lymphocytes. Ublituximab has been bioengineered for enhanced biological activity with an increased ability to trigger an immune response, delivering superior ADCC effects to aid in B-cell depletion. Ublituximab has displayed high single agent activity in a Phase I/II clinical trial in patients with relapsed Chronic Lymphocytic Leukemia, and is being developed by TG Therapeutics in multiple oncology and autoimmune indications. A Phase I/II clinical trial of ublituximab in patients with non-Hodgkin's lymphoma, relapsed or refractory to prior anti-CD20 therapy, is currently ongoing.